

Justin A Ezekowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3700036/publications.pdf>

Version: 2024-02-01

361
papers

35,811
citations

10986

71
h-index

3732

179
g-index

370
all docs

370
docs citations

370
times ranked

27996
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	27.0	7,537
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
3	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 2011, 365, 32-43.	27.0	1,133
4	The Effects of Climate Change on Cardiac Health. Cardiology, 2015, 131, 209-217.	1.4	1,123
5	HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, e1-e2.	1.7	1,086
6	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
7	Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes. Circulation, 2003, 107, 223-225.	1.6	789
8	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	27.0	753
9	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European Heart Journal, 2012, 33, 1750-1757.	2.2	652
10	Renal Insufficiency and Heart Failure. Circulation, 2004, 109, 1004-1009.	1.6	651
11	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	1.7	503
12	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502.	7.4	497
13	Meta-analysis: Î²-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. Annals of Internal Medicine, 2009, 150, 784.	3.9	426
14	Effect of Natriuretic Peptideâ€“Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	7.4	386
15	The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1587-1592.	2.8	331
16	Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. Journal of the American College of Cardiology, 2009, 53, 13-20.	2.8	309
17	Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101â€“Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 2017, 35, 870-877.	1.6	292
18	Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. Annals of Internal Medicine, 2004, 141, 381.	3.9	274

#	ARTICLE	IF	CITATIONS
19	Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, 475-539.	1.7	267
20	Implantable Cardioverter Defibrillators in Primary and Secondary Prevention. Annals of Internal Medicine, 2003, 138, 445.	3.9	234
21	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, The, 2016, 388, 2895-2903.	13.7	229
22	The "obesity paradox" in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Thromboembolic Complications in Atrial Fibrillation) Trial. JAMA - Journal of the American Medical Association, 2016, 315, 2869-2878.	2.2	194
23	N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2274-2284.	2.8	191
24	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. Journal of the American College of Cardiology, 2016, 67, 1444-1455.	2.8	191
25	Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery. Circulation, 2011, 124, 289-296.	1.6	186
26	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. Canadian Journal of Cardiology, 2013, 29, 168-181.	1.7	176
27	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet, The, 2012, 380, 1749-1758.	13.7	175
28	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	7.4	170
29	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 531-546.	1.7	170
30	Testosterone Supplementation in Heart Failure. Circulation: Heart Failure, 2012, 5, 315-321.	3.9	166
31	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. European Heart Journal, 2013, 34, 2464-2471.	2.2	154
32	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 309-314.	3.9	152
33	Impact of specialist follow-up in outpatients with congestive heart failure. Cmaj, 2005, 172, 189-194.	2.0	151
34	Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS ONE, 2015, 10, e0124844.	2.5	150
35	Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction. Annals of Internal Medicine, 2007, 147, 251.	3.9	146
36	Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. European Heart Journal, 2008, 30, 469-477.	2.2	145

#	ARTICLE	IF	CITATIONS
37	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104.	4.1	141
38	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. Canadian Journal of Cardiology, 2011, 27, 319-338.	1.7	139
39	Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. American Heart Journal, 2012, 164, 365-372.	2.7	139
40	Heart Failure Is a Risk Factor for Orthopedic Fracture. Circulation, 2008, 118, 1946-1952.	1.6	136
41	Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 451-460.	3.9	136
42	Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure. Mayo Clinic Proceedings, 2010, 85, 609-617.	3.0	135
43	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2018, 11, e004646.	3.9	134
44	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Canadian Journal of Cardiology, 2010, 26, 185-202.	1.7	125
45	The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. European Heart Journal, 2009, 30, 2584-2592.	2.2	121
46	Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. European Journal of Heart Failure, 2011, 13, 142-147.	7.1	116
47	The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. International Journal of Molecular Sciences, 2019, 20, 904.	4.1	116
48	Meta-analysis: Cardiac Resynchronization Therapy for Patients With Less Symptomatic Heart Failure. Annals of Internal Medicine, 2011, 154, 401.	3.9	113
49	Diuretic response in acute heart failure—an analysis from ASCEND-HF. American Heart Journal, 2015, 170, 313-321.e4.	2.7	110
50	Coenzyme Q10 and Heart Failure. Circulation: Heart Failure, 2016, 9, e002639.	3.9	108
51	Rationale and Design of the GUIDE-IT Study. JACC: Heart Failure, 2014, 2, 457-465.	4.1	106
52	Acute heart failure in the emergency department: Short and long-term outcomes of elderly patients with heart failure. European Journal of Heart Failure, 2008, 10, 308-314.	7.1	104
53	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. Circulation: Heart Failure, 2013, 6, 727-732.	3.9	103
54	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 2364-2373.	2.2	102

#	ARTICLE	IF	CITATIONS
55	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
56	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. <i>Canadian Journal of Cardiology</i> , 2015, 31, 3-16.	1.7	96
57	Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System. <i>Circulation: Heart Failure</i> , 2011, 4, 317-323.	3.9	95
58	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008, 24, 21-40.	1.7	93
59	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	1.7	93
60	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	1.7	89
61	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	4.1	88
62	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016, 32, 296-310.	1.7	86
63	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	4.1	84
64	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure. <i>Cmaj</i> , 2013, 185, E681-E689.	2.0	82
65	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. <i>JAMA Cardiology</i> , 2016, 1, 673.	6.1	81
66	Incidence of heart failure and mortality after acute coronary syndromes. <i>American Heart Journal</i> , 2013, 165, 379-385.e2.	2.7	80
67	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009, 25, 85-105.	1.7	79
68	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1177-1183.	2.8	78
69	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
70	Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. <i>BMC Cancer</i> , 2011, 11, 318.	2.6	76
71	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	6.1	74
72	Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. <i>Heart</i> , 2011, 97, 2046-2050.	2.9	73

#	ARTICLE	IF	CITATIONS
73	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2015, 21, 27-43.	1.7	73
74	The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. <i>CMAJ Open</i> , 2016, 4, E365-E370.	2.4	73
75	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	2.8	69
76	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	4.1	68
77	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. <i>BMJ: British Medical Journal</i> , 2005, 331, 873.	2.3	67
78	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet</i> , 2022, 399, 1391-1400.	13.7	67
79	Resource Use in the Last 6 Months of Life Among Patients With Heart Failure in Canada. <i>Archives of Internal Medicine</i> , 2011, 171, 211.	3.8	65
80	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	4.1	65
81	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
82	Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. <i>European Heart Journal</i> , 2019, 40, 2110-2117.	2.2	63
83	Oxygen Therapy in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 783-790.	4.1	62
84	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2022, 4, e46-e54.	12.3	62
85	Challenges in Systematic Reviews of Therapeutic Devices and Procedures. <i>Annals of Internal Medicine</i> , 2005, 142, 1100.	3.9	61
86	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	3.0	59
87	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	1.7	57
88	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	2.7	57
89	Cognitive decline in heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 661-673.	3.9	57
90	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. <i>European Journal of Heart Failure</i> , 2014, 16, 334-341.	7.1	56

#	ARTICLE	IF	CITATIONS
91	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection. Journal of the American College of Cardiology, 2019, 74, 2511-2524.	2.8	54
92	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	2.8	54
93	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. Journal of Cardiac Failure, 2013, 19, 371-389.	1.7	53
94	The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): A pilot study. American Heart Journal, 2015, 169, 274-281.e1.	2.7	53
95	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320.	7.1	53
96	Heart Failure Is a Clinically and Densitometrically Independent Risk Factor for Osteoporotic Fractures: Population-Based Cohort Study of 45,509 Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1179-1186.	3.6	50
97	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2012, 18, 265-281.	1.7	50
98	Early Follow-Up After a Heart Failure Exacerbation. Circulation: Heart Failure, 2016, 9, .	3.9	49
99	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <sc>MAGGIC</sc> meta-analysis. European Journal of Heart Failure, 2015, 17, 1182-1191.	7.1	48
100	Carotid chemoreceptor modulation of blood flow during exercise in healthy humans. Journal of Physiology, 2011, 589, 6219-6230.	2.9	47
101	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	1.6	47
102	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364.	2.2	47
103	Liver function tests in patients with acute heart failure and associated outcomes: insights from <sc>ASCEND-HF</sc>. European Journal of Heart Failure, 2016, 18, 424-432.	7.1	45
104	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. Canadian Journal of Cardiology, 2014, 30, 249-263.	1.7	44
105	External Validation of the H ₂ F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2019, 139, 2377-2379.	1.6	44
106	The Use of Î²-Blockers in a Tertiary Care Heart Failure Clinic. Archives of Internal Medicine, 2004, 164, 769.	3.8	43
107	Association between obesity and health-related quality of life in patients with coronary artery disease. International Journal of Obesity, 2010, 34, 1434-1441.	3.4	43
108	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.	3.9	42

#	ARTICLE	IF	CITATIONS
109	Variation in Critical Care Unit Admission Rates and Outcomes for Patients With Acute Coronary Syndromes or Heart Failure Among High- and Low-Volume Cardiac Hospitals. <i>Journal of the American Heart Association</i> , 2015, 4, e001708.	3.7	42
110	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	7.1	42
111	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
112	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions—A Consensus Document from the <sc>SAEM</sc>/<sc>HFSA</sc> Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2015, 22, 94-112.	1.8	41
113	Determinants of Early Readmission After Hospitalization for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 612-618.	1.7	40
114	The Unrecognized Burden of Osteoporosis-Related Vertebral Fractures in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 419-424.	3.9	39
115	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.1	39
116	Risk Stratification in Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 312-319.	1.7	39
117	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , 2018, 190, E1192-E1206.	2.0	39
118	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020, 142, 2231-2239.	1.6	39
119	The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. <i>American Heart Journal</i> , 2011, 161, 986-992.e1.	2.7	38
120	The Correlation of Standard Heart Failure Assessment and Palliative Care Questionnaires in a Multidisciplinary Heart Failure Clinic. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 379-387.	1.2	38
121	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	2.7	38
122	Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 259-268.	2.2	37
123	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	2.7	36
124	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	7.1	36
125	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-HF predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	7.1	36
126	Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.	2.8	35

#	ARTICLE	IF	CITATIONS
127	Practice-Level Variation in Use of Recommended Medications Among Outpatients With Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1132-1138.	3.9	35
128	The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction*. <i>Critical Care Medicine</i> , 2013, 41, 2080-2087.	0.9	35
129	Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. <i>International Journal of Cardiology</i> , 2013, 168, 2127-2133.	1.7	34
130	Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. <i>Heart</i> , 2018, 104, 1691-1698.	2.9	34
131	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
132	Heart Failure Re-Admission: Measuring the Ever Shortening Gap between Repeat Heart Failure Hospitalizations. <i>PLoS ONE</i> , 2014, 9, e106494.	2.5	33
133	Assessing the Use of International Classification of Diseases-10th Revision Codes From the Emergency Department for the Identification of Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 386-391.	4.1	33
134	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	3.9	33
135	Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades. <i>JAMA Cardiology</i> , 2019, 4, 1122.	6.1	32
136	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	3.9	32
137	Do stable non-“ST-segment elevation acute coronary syndromes require admission to coronary care units?. <i>American Heart Journal</i> , 2016, 175, 184-192.	2.7	31
138	Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria. <i>International Journal of Cardiology</i> , 2017, 228, 558-562.	1.7	31
139	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	3.9	30
140	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. <i>American Heart Journal</i> , 2010, 160, 272-278.	2.7	29
141	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	7.1	29
142	Usefulness of spironolactone in a specialized heart failure clinic. <i>American Journal of Cardiology</i> , 2004, 94, 443-447.	1.6	28
143	Changes in Heart Failure Outcomes After a Province-Wide Change in Health Service Provision A Natural Experiment in Alberta, Canada. <i>Circulation: Heart Failure</i> , 2013, 6, 76-82.	3.9	28
144	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1472-1477.	1.7	28

#	ARTICLE	IF	CITATIONS
145	Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Heart Failure, 2017, 4, 301-311.	3.1	28
146	Acute Heart Failure. Circulation: Heart Failure, 2012, 5, 735-741.	3.9	27
147	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovascular Disorders, 2014, 14, 91.	1.7	27
148	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clinical Research in Cardiology, 2018, 107, 170-181.	3.3	27
149	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—Insights from ASCEND-HF. European Journal of Heart Failure, 2020, 22, 1022-1031.	7.1	27
150	Comparison of Direct Body Composition Assessment Methods in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2010, 16, 867-872.	1.7	26
151	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). Journal of the American Heart Association, 2015, 4, .	3.7	26
152	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	26
153	N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Canadian Journal of Cardiology, 2006, 22, 393-397.	1.7	25
154	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 534-542.	2.2	25
155	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. Journal of the American Heart Association, 2015, 4, e002092.	3.7	25
156	Association Between Self-reported Adherence to a Low-Sodium Diet and Dietary Habits Related to Sodium Intake in Heart Failure Patients. Journal of Cardiovascular Nursing, 2015, 30, 58-65.	1.1	25
157	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. International Journal of Cardiology, 2020, 317, 167-173.	1.7	25
158	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care, 2022, 45, 204-212.	8.6	25
159	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. American Heart Journal, 2015, 169, 122-131.e22.	2.7	24
160	Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study. Clinical Nutrition ESPEN, 2016, 11, e26-e32.	1.2	24
161	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. European Journal of Heart Failure, 2018, 20, 1031-1038.	7.1	24
162	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. American Heart Journal, 2020, 227, 56-63.	2.7	24

#	ARTICLE	IF	CITATIONS
163	Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 130-139.	3.0	24
164	Do Anthropometric Indices Accurately Reflect Directly Measured Body Composition in Men and Women With Chronic Heart Failure?. <i>Congestive Heart Failure</i> , 2011, 17, 89-91.	2.0	23
165	Ethnic differences in 1-year mortality among patients hospitalised with heart failure. <i>Heart</i> , 2011, 97, 1048-1053.	2.9	23
166	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2017, 69, 712-744.	2.8	23
167	Ivabradine in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	23
168	Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017278.	3.7	23
169	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	4.1	23
170	CRYOPRESERVATION OF RAT PANCREATIC ISLETS. <i>Transplantation</i> , 1997, 64, 1065-1070.	1.0	23
171	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021094.	3.7	23
172	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	1.7	23
173	Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 106-113.	2.1	22
174	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	4.1	22
175	Dietary fatty acids intake and mortality in patients with heart failure. <i>Nutrition</i> , 2014, 30, 1366-1371.	2.4	22
176	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <scp>ASCEND-HF</scp>. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	7.1	22
177	Insights into the importance of the electrocardiogram in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1032-1040.	7.1	22
178	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	1.8	22
179	Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department. <i>Europace</i> , 2020, 22, 695-703.	1.7	22
180	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the <scp>PACT-HF</scp> randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1488-1498.	7.1	22

#	ARTICLE	IF	CITATIONS
181	Chloride in Heart Failure. JACC: Heart Failure, 2021, 9, 904-915.	4.1	22
182	Comparison of One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart Failure Patients With Left Ventricular Ejection Fraction $\geq 50\%$ Versus Those With Ejection Fraction $< 50\%$. American Journal of Cardiology, 2008, 102, 79-83.	1.6	21
183	Trends in death attributed to myocardial infarction, heart failure and pulmonary embolism in Europe and Canada over the last decade. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 813-820.	0.5	21
184	Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?. American Heart Journal, 2014, 168, 60-67.e5.	2.7	21
185	Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 81.	3.3	21
186	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	1.6	21
187	Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. BMC Cardiovascular Disorders, 2014, 14, 133.	1.7	20
188	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. Journal of the American College of Cardiology, 2018, 72, 2551-2562.	2.8	20
189	The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. Canadian Journal of Cardiology, 2005, 21, 165-71.	1.7	20
190	Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure. Journal of Cardiac Failure, 2004, 10, 165-173.	1.7	19
191	A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. Case Reports in Medicine, 2009, 2009, 1-3.	0.7	19
192	Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSESS IV-PCI) trial. American Heart Journal, 2010, 159, 131-140.	2.7	19
193	The high cost of critical care unit over-utilization for patients with NSTEMI ACS. American Heart Journal, 2018, 202, 84-88.	2.7	19
194	OUTSMART HF. Circulation, 2020, 141, 818-827.	1.6	19
195	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. Canadian Journal of Cardiology, 2020, 36, 1148-1151.	1.7	19
196	The Prevalence of Natural Health Product Use in Patients with Acute Cardiovascular Disease. PLoS ONE, 2011, 6, e19623.	2.5	19
197	Proportion of Patients Followed in a Specialized Heart Failure Clinic Needing an Implantable Cardioverter Defibrillator as Determined by Applying Different Trial Eligibility Criteria. American Journal of Cardiology, 2006, 97, 882-885.	1.6	18
198	Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. American Heart Journal, 2010, 160, 671-677.	2.7	18

#	ARTICLE	IF	CITATIONS
199	Diabetes, impaired fasting glucose, and heart failure: Its not all about the sugar. European Journal of Heart Failure, 2014, 16, 1153-1156.	7.1	18
200	Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. Critical Care Medicine, 2010, 38, 1793-1801.	0.9	17
201	Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010â€“2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network. Journal of the American Heart Association, 2018, 7, .	3.7	17
202	Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study. American Heart Journal, 2018, 202, 148-150.	2.7	17
203	Estimates of Dietary Sodium Consumption in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2015, 21, 981-988.	1.7	16
204	The Impact and Implications of Twitter for Cardiovascular Medicine. Journal of Cardiac Failure, 2017, 23, 266-267.	1.7	16
205	Prediction of Early Adverse Events in Emergency Department Patients With Acute Heart Failure: A Systematic Review. Canadian Journal of Cardiology, 2018, 34, 168-179.	1.7	16
206	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512.	1.6	16
207	High vs. low oxygen therapy in patients with acute heart failure: <scp>HiLoâ€“CHF</scp> pilot trial. ESC Heart Failure, 2019, 6, 667-677.	3.1	16
208	Substance and Substrate. Circulation, 2020, 141, 362-366.	1.6	16
209	Evidence-Based Management of Acute Heart Failure. Canadian Journal of Cardiology, 2021, 37, 621-631.	1.7	16
210	Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials. Current Heart Failure Reports, 2013, 10, 373-379.	3.3	15
211	Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients. Journal of Applied Physiology, 2015, 118, 839-848.	2.5	15
212	The future of cardiovascular clinical research in North America and beyondâ€“addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. American Heart Journal, 2015, 169, 743-750.	2.7	15
213	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. Circulation: Heart Failure, 2016, 9, .	3.9	15
214	Stroke: strategies for primary prevention. American Family Physician, 2003, 68, 2379-86.	0.1	15
215	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 840-846.	1.7	14
216	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. European Journal of Heart Failure, 2016, 18, 684-692.	7.1	14

#	ARTICLE	IF	CITATIONS
217	Composite End Points in Clinical Trials of Heart Failure Therapy. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
218	Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women. <i>Canadian Journal of Cardiology</i> , 2017, 33, 911-917.	1.7	14
219	Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2019, 21, 58.	3.3	14
220	Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 149-154.	1.9	14
221	Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 45-58.	1.0	14
222	Anemia in Patients With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2301.	2.8	13
223	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013, 168, 2315-2321.	1.7	13
224	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 267-273.e1.	2.7	13
225	Salt in the diet in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 196-203.	1.8	13
226	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016, 13, 140-148.	1.6	13
227	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e5-1038.e9.	1.7	13
228	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , 2017, 33, 166-169.	1.7	13
229	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	2.2	13
230	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. <i>Journal of Cardiac Failure</i> , 2021, 27, 602-606.	1.7	13
231	Cost-Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation. <i>Journal of the American Heart Association</i> , 2021, 10, e019599.	3.7	13
232	The Prognostic Importance of Changes in Renal Function during Treatment for Acute Heart Failure Depends on Admission Renal Function. <i>PLoS ONE</i> , 2015, 10, e0138579.	2.5	12
233	Interaction of Body Mass Index on the Association Between N-Terminal Pro-B-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study) Trial. <i>Association</i> , 2018, 7, .	3.7	12
234	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. <i>Open Heart</i> , 2018, 5, e000908.	2.3	12

#	ARTICLE	IF	CITATIONS
235	Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data. Canadian Journal of Cardiology, 2019, 35, 1412-1415.	1.7	12
236	Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients. Journal of Heart and Lung Transplantation, 2019, 38, 710-718.	0.6	12
237	Participation in a Heart Failure Clinical Trial. Circulation: Heart Failure, 2021, 14, e008242.	3.9	12
238	Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Failure, 2021, 8, 5352-5362.	3.1	12
239	Rates and reasons for device-based guideline eligibility in patients with heart failure. Heart Rhythm, 2014, 11, 1983-1990.	0.7	11
240	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). Canadian Journal of Cardiology, 2014, 30, 1208-1215.	1.7	11
241	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). BMJ Open, 2016, 6, e010201.	1.9	11
242	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	4.1	11
243	Subclinical Pulmonary Edema Is Associated With Reduced Exercise Capacity in HFpEF and HFrEF. Journal of the American College of Cardiology, 2017, 70, 1827-1828.	2.8	11
244	Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF). American Heart Journal, 2018, 205, 87-96.	2.7	11
245	The Relationship Between Heart-Failure Hospitalization and Mortality in Patients Receiving Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2019, 35, 413-421.	1.7	11
246	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 173-178.	1.4	10
247	A new pathway? Failure, fragility and fractures. European Heart Journal, 2010, 31, 9-11.	2.2	10
248	Time to Energize Coenzyme Q 10 for Patients With Heart Failure? —. JACC: Heart Failure, 2014, 2, 650-652.	4.1	10
249	Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. PLoS ONE, 2015, 10, e0140607.	2.5	10
250	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. ESC Heart Failure, 2018, 5, 19-26.	3.1	10
251	Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography, 2018, 35, 1746-1754.	0.9	10
252	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. CJC Open, 2020, 2, 151-160.	1.5	10

#	ARTICLE	IF	CITATIONS
253	Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 220-228.	1.2	10
254	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	10
255	The epidemiology and management of elderly patients with myocardial infarction or heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 407-413.	3.9	9
256	Neither Diabetes nor Glucose-Lowering Drugs Are Associated With Mortality After Noncardiac Surgery in Patients With Coronary Artery Disease or Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 423-428.	1.7	9
257	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	1.7	9
258	Mortality Outcomes Among Status Aboriginals and Whites With Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 619-626.	1.7	9
259	Factors Associated With Natriuretic Peptide Testing in Patients Presenting to Emergency Departments With Suspected Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 986.e1-986.e8.	1.7	9
260	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 409-416.	1.7	9
261	Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1356.e21-1356.e28.	1.7	9
262	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, e000022.	2.2	9
263	Effects of age, gender, and risk factors for heart failure on native myocardial T_1 and extracellular volume fraction using the SASHA sequence at 1.5T. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1307-1317.	3.4	9
264	Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. <i>European Journal of Heart Failure</i> , 2011, 13, 1211-1215.	7.1	8
265	Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data. <i>International Journal of Biometeorology</i> , 2013, 57, 401-408.	3.0	8
266	Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 13.	2.0	8
267	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	1.7	8
268	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
269	Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat. <i>Journal of Cardiac Failure</i> , 2022, 28, 1298-1308.	1.7	8
270	Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada. <i>Scientific Reports</i> , 2022, 12, .	3.3	8

#	ARTICLE	IF	CITATIONS
271	Testosterone Therapy in Women With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1317-1319.	2.8	7
272	Myocardial Deformation Analysis in Contrast Echocardiography: First Results Using Two-Dimensional Cardiac Performance Analysis. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 1282-1289.	2.8	7
273	Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 365-376.	2.2	7
274	External Validation and Refinement of Emergency Heart Failure Mortality Risk Grade Risk Model in Patients With Heart Failure in the Emergency Department. <i>CJC Open</i> , 2019, 1, 123-130.	1.5	7
275	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2725-2733.	3.1	7
276	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e024833.	3.7	7
277	Update on the diagnosis and management of acute heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 202-206.	1.8	6
278	Eligibility of sodium-glucose cotransporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. <i>ESC Heart Failure</i> , 2020, 7, 275-279.	3.1	6
279	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019712.	3.7	6
280	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021, 18, 253-263.	3.3	6
281	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
282	Routine versus selective cardiac magnetic resonance in non-ischemic heart failure – OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). <i>Trials</i> , 2013, 14, 332.	1.6	5
283	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017, 188, 127-135.	2.7	5
284	Dietary Self-management in Heart Failure: High Tech or High Touch?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 19.	0.9	5
285	Screening and Initiating Supportive Care in Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 151.	2.4	5
286	Heart failure treatment and the art of medical decision making. <i>European Journal of Heart Failure</i> , 2019, 21, 1510-1514.	7.1	5
287	Design and Region-Specific Adaptation of the Dietary Intervention Used in the SODIUM-HF Trial: A Multicentre Study. <i>CJC Open</i> , 2020, 2, 8-14.	1.5	5
288	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020, 74, e13625.	1.7	5

#	ARTICLE	IF	CITATIONS
289	Underrepresentation of Women in Cardiovascular Randomized Clinical Trials. Canadian Journal of Cardiology, 2020, 36, 969.e7-969.e8.	1.7	5
290	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). Journal of Cardiovascular Translational Research, 2020, 13, 540-548.	2.4	5
291	Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. CJC Open, 2021, 3, 361-366.	1.5	5
292	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC: Heart Failure, 2021, 9, 497-505.	4.1	5
293	The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada. Journal of Cardiac Failure, 2022, 28, 237-246.	1.7	5
294	Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 195-201.	4.0	5
295	Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. European Heart Journal, 2009, 30, 2213-2219.	2.2	4
296	Novel Pharmacologic Therapies in Development for Acute Decompensated Heart Failure. Current Cardiology Reports, 2013, 15, 329.	2.9	4
297	Letter by Brown and Ezekowitz Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective". Circulation, 2017, 135, e889-e891.	1.6	4
298	Insights on the Use of Twitter at the Canadian Cardiovascular Congress. Canadian Journal of Cardiology, 2018, 34, 813.e7-813.e8.	1.7	4
299	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. JACC: Heart Failure, 2018, 6, 298-307.	4.1	4
300	Incremental costs of high intensive care utilisation in patients hospitalised with heart failure. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 660-666.	1.0	4
301	Frailty modelling for multitype recurrent events in clinical trials. Statistical Modelling, 2019, 19, 140-156.	1.1	4
302	Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population. Circulation: Heart Failure, 2020, 13, e006952.	3.9	4
303	The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Heart Failure. Frontiers in Physiology, 2020, 11, 195.	2.8	4
304	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 297-308.	1.7	4
305	Successful cryopreservation of rat islets using ethylene glycol. Transplantation Proceedings, 1997, 29, 1983.	0.6	3
306	Heart failure: can we define, assess, and treat diastolic heart failure?. European Journal of Heart Failure, 2012, 14, 713-715.	7.1	3

#	ARTICLE	IF	CITATIONS
307	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	2.8	3
308	How to Do More With Less. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 460-462.	2.2	3
309	Elevated Blood Pressure and Associations with Sodium Intake Among Multiethnic Youth in Edmonton, Canada: Findings from WHY ACT NOW. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 239-249.	2.2	3
310	Impact of Atrial Fibrillation Case Volume in the Emergency Department on Early and Late Outcomes of Patients With New Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2021, 78, 242-252.	0.6	3
311	The influence of comorbidities on achieving an Ñterminal proß-type natriuretic peptide target: a secondary analysis of the GUIDEß trial. <i>ESC Heart Failure</i> , 2021, , .	3.1	3
312	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. <i>Contemporary Clinical Trials</i> , 2022, 113, 106646.	1.8	3
313	Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. <i>ESC Heart Failure</i> , 2022, 9, 1564-1573.	3.1	3
314	Fluid Restriction: Time to Let it Flow?. <i>Journal of Cardiac Failure</i> , 2022, 28, 1480-1481.	1.7	3
315	What Price to Pay?. <i>Circulation</i> , 2009, 119, 368-370.	1.6	2
316	Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. <i>Annals of Internal Medicine</i> , 2009, 150, JC5.	3.9	2
317	Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. <i>International Journal of Cardiology</i> , 2015, 182, 184-186.	1.7	2
318	Identifying Lowß-risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (<sc>PROACT</sc>) 3 and 4 Trials. <i>Academic Emergency Medicine</i> , 2017, 24, 691-700.	1.8	2
319	Multitype Events and the Analysis of Heart Failure Readmissions. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	2
320	Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1365-1368.	1.7	2
321	A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart FunctionßClinics. <i>CJC Open</i> , 2019, 1, 173-181.	1.5	2
322	Creating order out of chaos: quality of care in heart failure. <i>Heart</i> , 2019, 105, 429-430.	2.9	2
323	Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With HeartßFailure. <i>Canadian Journal of Diabetes</i> , 2020, 44, 103-110.	0.8	2
324	Comparative Effectiveness of Primary Prevention Implantable CardioverterßDefibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	3.7	2

#	ARTICLE	IF	CITATIONS
325	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users. <i>CJC Open</i> , 2022, 4, 180-188.	1.5	2
326	Power and Sample Size Estimation for Nonparametric Composite Endpoints: Practical Implementation using Data Simulations. <i>Journal of Modern Applied Statistical Methods</i> , 2017, 16, 215-230.	0.2	2
327	A Call to Action: Cardiac Palliative Care. <i>Journal of Palliative Medicine</i> , 2009, 12, 289-290.	1.1	1
328	Response to Letter Regarding Article, "Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery: An Analysis of 38 047 Patients". <i>Circulation</i> , 2012, 125, .	1.6	1
329	The Timing of Implantable Cardioverter-Defibrillator Implantation in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 299-307.	2.9	1
330	Do Anticoagulants or Antiplatelet Drugs Have a Role in Treating Heart Failure in the Absence of Atrial Fibrillation?. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 435-438.	4.7	1
331	Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 86.	6.1	1
332	Oxygen therapy in acute myocardial infarctions: do we need to re-evaluate its necessity?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 693-694.	1.5	1
333	Examining the Influence of Component Outcomes on the Composite at the Design Stage. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004419.	2.2	1
334	Is incentivising stroke prevention therapy in atrial fibrillation the key?. <i>Heart</i> , 2019, 105, 4-5.	2.9	1
335	2017 Guidelines for the management of heart failure by pharmacists. <i>Canadian Pharmacists Journal</i> , 2019, 152, 301-316.	0.8	1
336	All for one, but not one for all. <i>European Heart Journal</i> , 2020, 41, 642-644.	2.2	1
337	Residuals. <i>Circulation</i> , 2021, 144, 438-440.	1.6	1
338	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	1.6	1
339	The waiting game: facing the consequences. <i>Cmaj</i> , 2002, 167, 1247-8.	2.0	1
340	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. <i>Progress in Cardiovascular Diseases</i> , 2022, , .	3.1	1
341	Defibrillators and Sudden Death. <i>Annals of Internal Medicine</i> , 2003, 139, W-85.	3.9	0
342	Time-dependent analysis in CHF follow-up. <i>Cmaj</i> , 2005, 173, 238-239.	2.0	0

#	ARTICLE	IF	CITATIONS
343	Response to Letter Regarding Article, "Heart Failure Is a Risk Factor for Orthopedic Fracture: A Population-Based Analysis of 16 294 Patients" Circulation, 2009, 120, .	1.6	0
344	Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. Evidence-Based Medicine, 2011, 16, 138-139.	0.6	0
345	Reply. JACC: Heart Failure, 2015, 3, 271-272.	4.1	0
346	Heart failure guidelines fail. Cmaj, 2015, 187, 912.2-912.	2.0	0
347	Re. "Dietary fatty acids intake and mortality in patients with heart failure" Authors' response. Nutrition, 2015, 31, 1185-1186.	2.4	0
348	Heterogeneity across one disease, two drugs, three trials, and four guidelines: are we further ahead?. European Journal of Heart Failure, 2016, 18, 1244-1247.	7.1	0
349	Letter by McAlister and Ezekowitz Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings From Get With the Guidelines-Heart Failure" Circulation: Heart Failure, 2016, 9, .	3.9	0
350	Diabetes and heart failure in the crosshairs: where is the target?. European Journal of Heart Failure, 2017, 19, 66-68.	7.1	0
351	Navigating Choices Among a Sea of Comorbidities —. Journal of the American College of Cardiology, 2017, 69, 2380-2382.	2.8	0
352	Letter by Kaul et al Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012" Circulation, 2017, 136, 884-885.	1.6	0
353	Effects of age, gender, and risk-factors for heart failure on native myocardial T1 and extracellular volume fraction using the SASHA sequence at 1.5T. Journal of Magnetic Resonance Imaging, 2018, 48, spcone-spcone.	3.4	0
354	Reply to McClure et al. "Reader Commentary on 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2018, 34, 813.e3.	1.7	0
355	Management of Comorbidities in Heart Failure. , 2020, , 687-696.e2.		0
356	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. Journal of Cardiac Failure, 2021, 27, 934-941.	1.7	0
357	Effect of low-dose dopamine on cardiorespiratory physiology in heart failure patients. FASEB Journal, 2013, 27, 928.6.	0.5	0
358	Optimizing Therapy of Heart Failure in the Aging Population with Monitoring in Clinics. , 2014, , 85-93.		0
359	Press 1 to Speak to a Representative. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007297.	2.2	0
360	Nationwide study of sex differences in incident heart failure in newly diagnosed nonvalvular atrial fibrillation. CJC Open, 2022, , .	1.5	0

#	ARTICLE	IF	CITATIONS
361	Surprise outcome for SODIUM-HF. , 0, , .		0